Overcoming trastuzumab resistance in HER2‐positive breast cancer using combination therapy
A Derakhshani, Z Rezaei, H Safarpour… - Journal of cellular …, 2020 - Wiley Online Library
Human epidermal growth factor receptor 2 (HER2)‐positive breast cancer (BC) comprises
around 20–30% of all BC subtypes and is correlated with poor prognosis. For many years …
around 20–30% of all BC subtypes and is correlated with poor prognosis. For many years …
[HTML][HTML] Roles and mechanisms of miR-195–5p in human solid cancers
Q Xu, JL Xu, WQ Chen, WX Xu, YX Song… - Biomedicine & …, 2022 - Elsevier
Cancer persists as a worldwide disease that contributes to high morbidity and mortality
rates. As a class of non-coding RNA, microRNAs (miRNAs) are one kind of important …
rates. As a class of non-coding RNA, microRNAs (miRNAs) are one kind of important …
MiR-132 inhibits migration and invasion and increases chemosensitivity of cisplatin-resistant oral squamous cell carcinoma cells via targeting TGF-β1
L Chen, Q Zhu, L Lu, Y Liu - Bioengineered, 2020 - Taylor & Francis
Numerous findings have demonstrated that MicroRNAs dysregulation plays a key role in
many neoplasms, including oral squamous cell carcinoma (OSCC), yet the potential …
many neoplasms, including oral squamous cell carcinoma (OSCC), yet the potential …
Gene expression and miRNAs profiling: function and regulation in human epidermal growth factor receptor 2 (HER2)-positive breast cancer
RM Sareyeldin, I Gupta, I Al-Hashimi, HA Al-Thawadi… - Cancers, 2019 - mdpi.com
Breast cancer is the second most common cause of cancer-related deaths among women
worldwide. It is a heterogeneous disease with four major molecular subtypes. One of the …
worldwide. It is a heterogeneous disease with four major molecular subtypes. One of the …
[HTML][HTML] miR-340: A multifunctional role in human malignant diseases
Z Huang, Y Xu, M Wan, X Zeng, J Wu - International Journal of …, 2021 - ncbi.nlm.nih.gov
MicroRNAs (miRNAs) are a class of short non-coding RNAs of approximately 22 nucleotides
in length, which function by binding to the 3'UTR sequences of their target mRNAs. It has …
in length, which function by binding to the 3'UTR sequences of their target mRNAs. It has …
The role of MicroRNAs in HER2-Positive breast Cancer: where we are and future prospective
V Fogazzi, M Kapahnke, A Cataldo, I Plantamura… - Cancers, 2022 - mdpi.com
Simple Summary Breast cancer is the most diagnosed malignancy in woman worldwide
and, despite the availability of new innovative therapies, it remains the first cause of death …
and, despite the availability of new innovative therapies, it remains the first cause of death …
Development of a microRNA panel for classification of abnormal mammograms for breast cancer
Simple Summary Breast cancer screening by mammography suffers from high rates of false
positivity, resulting in unnecessary investigative imaging and biopsies. There is an unmet …
positivity, resulting in unnecessary investigative imaging and biopsies. There is an unmet …
Effect of polyphenols on HER2-positive breast cancer and related miRNAs: Epigenomic regulation
ME Zabaleta, TY Forbes-Hernández… - Food Research …, 2020 - Elsevier
HER2-positive breast cancer is one of the most aggressive subtypes accounting for nearly
30% of diagnosed cases. It is associated with reduced disease-free survival, tumor …
30% of diagnosed cases. It is associated with reduced disease-free survival, tumor …
[HTML][HTML] Propofol reduces epithelial to mesenchymal transition, invasion and migration of gastric cancer cells through the microRNA-195-5p/snail axis
F Liu, F Qiu, M Fu, H Chen, H Wang - Medical Science Monitor …, 2020 - ncbi.nlm.nih.gov
Propofol Reduces Epithelial to Mesenchymal Transition, Invasion and Migration of Gastric
Cancer Cells through the MicroRNA-195-5p/Snail Axis - PMC Back to Top Skip to main content …
Cancer Cells through the MicroRNA-195-5p/Snail Axis - PMC Back to Top Skip to main content …
Targeted therapy modulates the secretome of cancer-associated fibroblasts to induce resistance in HER2-positive breast cancer
M Luque, M Sanz-Álvarez, A Santamaría… - International Journal of …, 2021 - mdpi.com
The combination of trastuzumab plus pertuzumab plus docetaxel as a first-line therapy in
patients with HER2-positive metastatic breast cancer has provided significant clinical …
patients with HER2-positive metastatic breast cancer has provided significant clinical …